z-logo
Premium
Differential effect of NMDA and AMPA receptor blockade on protein synthesis in the rat infarct borderzone
Author(s) -
Christensen T.,
Bruhn T.,
Frank L.,
Diemer N. H.
Publication year - 1996
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1996.tb00193.x
Subject(s) - nbqx , penumbra , ampa receptor , neuroprotection , glutamate receptor , nmda receptor , antagonist , dizocilpine , anesthesia , striatum , brain ischemia , ischemia , medicine , pharmacology , chemistry , receptor , dopamine
We investigated whether the known neuroprotective effects of two selective glutamate receptor antagonists, the NMDA antagonist MK‐801 and the AMPA antagonist NBQX, are reflected in the regional cerebral protein synthesis rates (CPSR) in rats with middle cerebral artery occlusion (MCAO). Rats treated with either saline, MK‐801 (5 mg/kg i.p.) or NBQX (30 mg/kg i.p. × 3) were subjected to permanent MCAO. Regional CPSR and volumes of gray matter structures displaying normal CPSR were measured in coronal cryosections of the brain by quantitative autoradiography following an i.v. bolus injection of 35 S‐labelled l ‐methionine 2 h after occlusion. MCAO completely inhibited protein synthesis in the lateral part of striatum and part of the adjacent frontoparietal cortex corresponding to the ischemic focus. Surrounding this, a metabolic penumbra with approximately 50% reductions in CPSR was present. Treatment with MK‐801 significantly increased the volume of tissue with normal CPSR in the ischemic hemisphere compared to controls, whereas this was not seen with NBQX treatment. The results suggest that MK‐801 and NBQX have different effects on periinfarct protein synthesis after MCAO. Since both compounds reduce infarct size, it is questionable that acute inhibition of protein synthesis in focal ischemia is of significant importance to the final outcome of a stroke lesion.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here